|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
|
2024 |
|
|
2023 |
|
| |
|
For the Three Months Ended March 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Convertible notes payable |
|
|
411,430 |
|
|
|
454,874 |
|
| Restricted stock units |
|
|
25,307 |
|
|
|
4,295 |
|
| Warrants to purchase shares of common stock |
|
|
124,159 |
|
|
|
314,462 |
|
| Total potentially dilutive shares |
|
|
560,896 |
|
|
|
773,631 |
|
|